证券研究报 告 宏观研究 【每周经济观察】 春节假期海外四大要闻——海外周报第 128 期 1、股市：全球主要股指多数上涨，韩股、法股、英股涨幅领先。2 月 16 日 ~20日，韩国综合指数、法国 CAC40、富时 100、欧洲斯托克 600指数、纳斯 达克、德国 DAX、标普 500、MSCI 新兴市场指数和道琼斯分别上涨 5.5%、 2.5%、2.3%、2.1%、1.5%、1.4%、1.1%、1.0%、 0.8%和 0.3%；恒生指数和 日经 225 分别下跌 0.6%和 0.2%。 2、债券：除美债利率外，全球主要 10 年期国债收益率多数下行。2 月 16 日 ~20 日，10 年期日债、法债、英债和意债收益率分别下行 6.1bps、3.8bps、 2.7bps 和 2.3bps；10 年期美债收益率上行 4.0bps。 3、大宗：全球主要大宗商品多数上涨。2 月 16 日~20 日，布伦特原油、WTI 原油、伦敦现货白银、伦敦现货黄金和 LME 期铜分别上涨 5.9%、5.7%、 4.1%、1.2%和 0.0%。 4、汇率：主要货币中日元、英镑跌幅较大。2 月 16 日~20 日，日元和英镑分 别下 ...

Investment Rating - The report maintains a "Recommendation" rating for the aviation industry, expecting the industry index to outperform the benchmark index by more than 5% in the next 3-6 months [47]. Core Insights - The Spring Festival travel season has seen a record high in cross-regional personnel flow, with an estimated total of 5.08 billion trips in the first 20 days, averaging 250 million trips per day, which is a 5.6% increase compared to the same period in 2025 [9][10]. - The aviation sector has shown strong performance in both passenger volume and ticket prices, with a 5.4% year-on-year increase in passenger volume and a 3.3% increase in average ticket prices during the same period [10][11]. - The 2026 Spring Festival is characterized by two main trends: "secondary travel" and "concentrated return trips," driven by a later Spring Festival and longer holiday period [12][13]. Summary by Sections Passenger Volume and Pricing - In the first 20 days of the Spring Festival, the average daily passenger volume for civil aviation reached 2.376 million, a 5.4% increase year-on-year, while the average ticket price was 1003 yuan, up 3.3% year-on-year [10][11]. - The domestic average passenger load factor was 85.1%, reflecting a 1.1% increase year-on-year, indicating strong demand [11]. Market Dynamics - Six listed airlines collectively withdrew 5 aircraft in January 2026, indicating a tightening supply constraint in the industry [26]. - The report highlights that except for Spring Airlines, all other major airlines have shown negative year-on-year growth in capacity deployment, with Spring Airlines leading at 4.5% growth [26]. Demand and Future Outlook - The demand structure in the aviation industry is improving, with a rebound in business travel sentiment since September 2025 [34]. - The introduction of visa-free policies for Canada and the UK starting February 17, 2026, is expected to boost cross-border travel demand [34]. - High passenger load factors are anticipated to lead to increased price elasticity, with the potential for significant price increases in 2026 [35]. Recommendations - The report recommends focusing on major airlines such as Air China, China Southern Airlines, and China Eastern Airlines for potential elasticity release, as well as low-cost carrier Spring Airlines for its core competitive advantages [35].

Investment Rating - The report maintains a "Recommendation" rating for the shipping industry, indicating an expectation of growth exceeding the benchmark index by more than 5% in the next 3-6 months [6]. Core Insights - The VLCC market is experiencing unprecedented high sentiment driven by geopolitical risk premiums, aggressive capacity expansion by Changjin Shipping, and strengthened sanctions [1][9]. - The geopolitical situation between the US and Iran continues to elevate risk premiums, with Brent crude oil futures reaching $71.76 per barrel, a week-on-week increase of 5.9% [2][19]. - Changjin Shipping has rapidly expanded its fleet, becoming the largest VLCC operator globally, controlling 118 VLCCs, which corresponds to a market share of 16% [2][20][21]. - Strengthened sanctions are increasing the demand for compliant trade, with Venezuela's oil shifting towards compliant markets and India committing to stop purchasing Russian oil, which could add 1% to global tanker trade [3][39]. - The EU's proposal for a comprehensive ban on maritime services for Russian oil could necessitate the transfer of more compliant vessels into shadow fleets, impacting supply dynamics [4][43]. Summary by Sections Market Review - VLCC rates have surged to their highest levels in nearly a decade, with the Clarksons VLCC-TCE reaching $142,000 per day, a week-on-week increase of 24.5% [9][12]. - The stock performance of tanker companies has been strong, with notable increases during the holiday period [16]. Geopolitical Factors - The ongoing US-Iran negotiations have not yielded clear outcomes, maintaining military tensions and affecting oil transport routes, particularly in the Strait of Hormuz [2][19]. - Changjin Shipping's aggressive market entry reflects confidence in the tanker market's high profitability, with a significant increase in the concentration of top VLCC owners [21]. Sanctions and Compliance - The report highlights a shift in the oil market towards compliance due to increased enforcement of sanctions, with Venezuela's oil exports moving towards compliant channels [3][38]. - The EU's proposed ban on maritime services for Russian oil could lead to a significant increase in the demand for compliant vessels [4][43]. Investment Recommendations - The report emphasizes a bullish outlook for the oil transportation market, with expectations of continued demand growth and limited supply, recommending specific companies within the sector [5][46].

Market Performance - Global major stock indices mostly rose, with the Korean Composite Index, French CAC40, and FTSE 100 leading with increases of 5.5%, 2.5%, and 2.3% respectively from February 16 to 20[2] - Major 10-year government bond yields mostly declined, with Japanese, French, British, and Italian bonds down by 6.1bps, 3.8bps, 2.7bps, and 2.3bps respectively, while the 10-year U.S. Treasury yield rose by 4.0bps[2] - Most major commodities saw price increases, with Brent crude oil and WTI crude oil rising by 5.9% and 5.7% respectively during the same period[2] Currency Movements - The Japanese yen and British pound experienced significant declines, falling by 1.5% and 1.3% respectively, while the U.S. dollar index rose by 0.9%[3] Geopolitical Events - The U.S.-Iran crisis escalated, with WTI crude oil prices increasing from approximately $62.33 to $66.39, marking a 6.5% rise, and Brent crude oil rising by 6.4% to $71.76 due to military tensions in the region[3] - The FOMC meeting minutes indicated a neutral yet hawkish stance, with market expectations for a potential rate cut of about 60 basis points this year, reflecting a slight easing compared to previous expectations[4] Legal and Trade Developments - The U.S. Supreme Court ruled against Trump's "emergency" tariffs, leading to a significant shift in trade policy, with Trump announcing a new 10% tariff on global imports for 150 days[5] - Following the Supreme Court's decision, the market reacted positively, with the Nasdaq index rising by 0.90% due to eased supply chain pressures[7] Economic Outlook - Japan's new Prime Minister, Fumio Kishida, emphasized a "responsible active fiscal policy," proposing significant tax cuts and public investments, which are expected to boost Japan's GDP growth forecast for 2026[8]

Policy Direction - The policy emphasizes "stability while seeking progress" and aims for a good start to the "14th Five-Year Plan" with a focus on counter-cyclical adjustments and short-term economic stability, warning against "policy dependency" without reform support[1] - Investment should not follow the old path of "rapid expansion" but focus on the real economy and technological innovation, with an emphasis on improving people's livelihoods and human resource development[2] Investment and Consumption - The government plans to optimize the implementation of "dual heavy" projects and increase central investment subsidy standards, while enhancing the management of local government special bonds to boost project construction[2] - There is a commitment to increase basic pensions for urban and rural residents and to release potential in service consumption sectors such as tourism, events, dining, and health care[3] Market Competition and Industry Development - Measures will be taken to regulate "involution-style" competition through a list of encouraged and prohibited items for local government investment, aiming to create a fair market order[3] - The focus will be on developing emerging pillar industries such as integrated circuits, aerospace, and biomedicine, while emphasizing the importance of artificial intelligence as a key variable[4] Risk Management - The report highlights the need to manage risks in key areas, including supporting reasonable financing needs of real estate companies and preventing debt default risks[9] - It calls for optimizing debt restructuring and replacement methods to mitigate risks associated with local government financing platforms[10]

Investment Rating - The industry investment rating is "Recommended" [3][45] Core Viewpoints - In January, the total slaughter volume of 18 sample pig companies increased by 12.54% year-on-year but decreased by 11.15% month-on-month, totaling 18.02 million heads [6][9] - The average selling price of commercial pigs for 15 sample pig companies in January was 12.58 yuan/kg, a year-on-year decrease of 19.30% but an increase of 8.83% month-on-month [13][14] - The average weight of slaughtered pigs in January was 121.41 kg, showing a year-on-year increase of 2.82% and a month-on-month increase of 1.42% [16][17] - The industry is experiencing a return to losses in breeding profits before the festival, with the average weight of pigs still at historically high levels [19][20] - The current valuation level of the pig farming sector is relatively low, with sufficient safety margins, and the cost advantages of leading companies like Muyuan are expected to expand [34][35] Summary by Sections Slaughter Volume - In January, the total slaughter volume of 18 sample pig companies was 18.02 million heads, with a year-on-year increase of 12.54% and a month-on-month decrease of 11.15% [6][9][11] Selling Price - The average selling price of commercial pigs in January was 12.58 yuan/kg, down 19.30% year-on-year but up 8.83% month-on-month [13][14][16] Average Weight - The average weight of slaughtered pigs was 121.41 kg in January, reflecting a year-on-year increase of 2.82% and a month-on-month increase of 1.42% [16][17][19] Industry Overview - The industry is facing a return to losses in breeding profits, with the average weight of pigs remaining high historically [19][20][34] Investment Recommendations - The report suggests a forward-looking layout at the bottom, emphasizing efficiency over growth and quality over scale, with a focus on companies like Muyuan, Wens, Dekang, and Shennong [33][34][35]

Investment Rating - The report maintains a positive outlook on the blood products industry, suggesting that the supply-demand relationship will gradually improve, leading to performance recovery for companies in this sector [10][34]. Core Insights - The blood products industry is characterized by a clear long-term growth trajectory, supported by a favorable regulatory environment for plasma collection and an expanding product range among companies [12][34]. - Short-term performance has been impacted by supply-demand mismatches, with a notable decline in profitability observed in 2025 due to excess supply and price reductions [19][36]. - The report highlights the importance of white albumin and immunoglobulin (IVIG) as core products, with a stable demand expected despite recent price pressures [33][34]. Summary by Sections Market Review - The report notes a decline of 0.85% in the medical index, underperforming the CSI 300 index by 1.22 percentage points, ranking 21st among 30 sectors [6]. - The top-performing stocks in the medical sector include Aidi Te, Zhendai Medical, and Olin Bio, while the worst performers include Beixin Life and Huayuan Bio [6]. Industry and Stock Events - The report emphasizes the recovery of plasma collection activities post-pandemic, which has led to increased supply and a shift in the market dynamics for blood products [19][26]. - The report identifies key companies to watch, including Tian Tan Biological and Bo Ya Biological, as they are expected to benefit from the industry's growth [12][34]. Overall Perspective and Investment Themes - The report suggests focusing on innovative drugs, medical devices, and the blood products sector, highlighting the potential for significant growth driven by domestic differentiation and international expansion [10][12]. - The report also discusses the ongoing consolidation in the industry, particularly among state-owned enterprises, which may enhance market concentration and operational efficiencies [46]. Supply and Demand Dynamics - The report indicates that the supply of blood products is expected to tighten in 2026 due to a slowdown in plasma collection growth and a decrease in imported white albumin supply [30][34]. - Demand for white albumin remains robust, with sales showing signs of stabilization despite recent challenges [33][34]. Future Outlook - The report anticipates a gradual return to a balanced supply-demand relationship in the blood products industry, which could lead to improved financial performance for key players [34][36]. - The potential for new product introductions and market expansions is highlighted as a significant driver for future growth in the sector [12][34].

Investment Rating - The report maintains a positive outlook on the blood products industry, suggesting that the sector has clear long-term growth potential due to increasing supply and demand elasticity [12][19][36]. Core Insights - The blood products industry is expected to benefit from a more relaxed approval process for plasma collection stations during the 14th Five-Year Plan, leading to increased production capacity and a diverse range of products [12][19]. - The report highlights a significant shift in the industry from a supply surplus to a supply-demand balance, with expectations for improved performance in 2026 as supply constraints tighten and demand remains stable [36][34]. - Key companies to watch include TianTan Biotech, BoYa Bio, and HuaLan Bio, which are expected to see performance improvements as the market stabilizes [12][36]. Summary by Sections Market Review - The report notes that the CITIC pharmaceutical index fell by 0.85%, underperforming the CSI 300 index by 1.22 percentage points, ranking 21st among 30 primary industries [6]. - The top-performing stocks in the sector included AidiTe and ZhenDe Medical, while stocks like BeiXin Life and HuaYuan Bio faced significant declines [6][12]. Industry and Stock Events - The blood products sector has experienced a prolonged adjustment period, with a cumulative decline of 18.1% since early 2025, significantly underperforming the broader pharmaceutical sector [16]. - The report indicates that the performance of major blood product companies has varied, with some like WeiGuang Bio and HuaLan Bio performing better than the sector average [16]. Overall Perspective and Investment Themes - The report emphasizes the transition from a quantity-driven to a quality-driven approach in the innovative drug sector, suggesting a focus on differentiated products and international expansion [10]. - In the medical device sector, there is a notable recovery in bidding volumes for imaging equipment, with companies like MaiRui and LianYing expected to benefit from ongoing upgrades [10]. - The report also highlights the importance of the CXO and life sciences services sectors, predicting a recovery in domestic investment and a return to high growth rates [10]. Blood Products - The blood products industry is characterized by a clear growth trajectory, with both supply and demand expected to show significant elasticity [12][19]. - The report suggests that the industry will see improved performance due to a combination of increased plasma collection and a tightening supply situation, which is expected to stabilize prices and enhance profitability for key players [36][34].

Group 1: Current Financial Data Analysis - In January 2026, the M2 growth was strong, with an increase of 3.6 trillion yuan month-on-month, ranking second highest in the observed data range, only behind 2024[17] - The growth of corporate deposits in January was exceptionally strong, with an increase of 1.4 trillion yuan month-on-month, representing 113% of the total increase for the previous year, the highest in the observed data range[19] - Non-bank deposits increased by 1.8 trillion yuan month-on-month, ranking second highest in the observed data range, with the increase accounting for approximately 21% of the total increase for the previous year[24] Group 2: Future Liquidity Outlook - Future liquidity appears to rely heavily on policy support, with weak consumer borrowing and direct financing through non-bank sectors[63] - The upcoming maturity of interbank certificates of deposit is expected to gradually decrease, which may impact liquidity levels[63] - The current liquidity easing is a fact, but under the "exit from unconventional" policy context, a marginal weakening of liquidity in 2026 compared to 2025 is likely[63] Group 3: Market Impact - The financial data does not yet provide a robust judgment on the recovery of domestic demand, indicating a continued reliance on exports[65] - The relationship between stocks and bonds remains unchanged, with the peak of the Shanghai Composite Index in January aligning with the peak of the ten-year government bond yield[65] - The bottom of bond yields is clearer than the top, as the probability of unconventional monetary easing by the central bank gradually decreases[65]

Investment Rating - The report maintains a "Recommendation" rating for the veterinary medicine industry, expecting the industry index to outperform the benchmark index by more than 5% in the next 3-6 months [80]. Core Insights - In January, the majority of vaccine varieties saw a year-on-year decline in batch approvals, with the Veterinary Product Index (VPI) dropping 1.8% month-on-month, marking three consecutive months of decline [2][3]. - The report highlights that the overall performance of the animal vaccine and veterinary medicine sector has been affected by high base effects from the previous year, low breeding sentiment, and the timing of the Spring Festival impacting stocking rhythms [10][57]. - The report emphasizes the importance of innovation in driving performance, noting that companies demonstrating product, marketing, or capital operation innovations have shown better financial results [71][72]. Summary by Sections Vaccine Batch Approvals - In January, most vaccine products experienced a year-on-year decline in batch approvals. For pig vaccines, the majority saw declines, with only pseudorabies and blue ear vaccines showing increases of 13.1% and 30.2%, respectively. Other vaccines like foot-and-mouth disease and porcine circovirus vaccines saw declines ranging from 20% to 50% [9][10]. - In the poultry vaccine segment, the H5N1 trivalent vaccine and Marek's vaccine saw declines of 13.8% and 25.9%, respectively, while the newcastle disease vaccine remained flat [9][10]. Veterinary Raw Materials - The VPI index averaged 66.16 in January, down 1.8% from December, with a continued downward trend observed in the prices of most raw materials. For instance, the price of florfenicol dropped by 4.5% month-on-month, while amoxicillin saw a slight increase of 0.7% [57][58]. - Year-on-year comparisons show that while some products like tylosin and tilmicosin have seen significant price increases, amoxicillin has dropped by 28.8% [58][57]. Investment Recommendations - The report suggests focusing on undervalued companies with improvement logic, highlighting that the ongoing industry competition has led to a market environment where only innovative companies are likely to thrive. Recommended companies include Zhongmu Co., Ltd., Reap Bio, and others [71][73].